Showing 1221-1230 of 1478 results for "".
- Survey: Despite Knowledge, Parents Don't Drive Kids' Sunscreen Usehttps://practicaldermatology.com/news/survey-despite-knowledge-parents-dont-drive-kids-sunscreen-use/2458142/According to a new Neutrogena Survey conducted online by Harris Poll, more than 4 in 5 parents of children under 18 years old say their children do not wear sunscreen on a daily basis— despite over 9 in 10 Americans believing sunscreen is important for protecting a child’s health.
- Wontech's Pico Laser Gets FDA Nodhttps://practicaldermatology.com/news/wontechs-pico-laser-gets-fda-nod/2458146/The U.S. Food and Drug Administration (FDA) cleared WONTECH’s picosecond laser device for tattoo removal. PICOCARE removes tattoos in various colors in less time with 1064nm, 532nm, 595nm, and 660nm wavelengths and selectively removes pigment par
- Senate Unveils Health Care Proposalhttps://practicaldermatology.com/news/senate-unveils-health-care-proposal/2458147/The newly unveiled Senate Republican leadership’s health care proposal, the Better Care Reconciliation Act of 2017, would roll back much of the Affordable Care Act (ACA). According to media reports, the 142-page bill calls for: Elimination of the individual and e
- Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADEhttps://practicaldermatology.com/news/kristin-chenoweth-kicks-off-less-red-more-you-campaign-to-launch-rhofade/2458177/Emmy and Tony award-winning actress and singer Kristin Chenoweth is kicking off Allergan’s Rhofade "Less Red, More You" campaign. Chenoweth, who has rosacea, will begin a nationwide conversation about the condition while raising a
- Fibrocell to Continue Phase 1/2 Clinical Trial of FCX-007 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-to-continue-phase-12-clinical-trial-of-fcx-007-for-recessive-dystrophic-epidermolysis-bullosa/2458193/Fibrocell Science, Inc.’s Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), following a review of safety data from the first patient treated. No product-re
- BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acnehttps://practicaldermatology.com/news/biopharmx-reports-positive-topline-results-of-bpx-01-topical-minocycline-for-acne/2458198/BioPharmX Corporation’s topical minocycline for acne, BPX-01, achieved its primary endpoint in a phase 2b clinical trial. There were statistically significant reductions in non-nodular inflammatory acne lesions when compared to vehicle in both the 1 percent and 2 percent doses of BP
- Allergan Officially Adds Coolsculpting to Portfoliohttps://practicaldermatology.com/news/allergan-adds-coolsculpting-to-portfolio/2458207/It’s a done deal. Allergan now owns ZELTIQ® Aesthetics. Allergan acquired ZELTIQ® Aesthetics for approximately $2.4 billion in cash. ZELTIQ® stockholders approved the transaction during its stockholder meeting h
- Paratek: Phase 3 Data Show Omadacycline Effective Against Common Skin Pathogens, Including MRSAhttps://practicaldermatology.com/news/paratek-phase-3-data-show-omadacycline-effective-against-common-skin-pathogens-including-mrsa/2458211/Analysis of microbiology data from a Phase 3 study of omadacycline in acute skin infections shows that once-daily treatment with IV-to-oral omadacycline is effective in treating the most frequently isolated bacterial pathogens associated with skin infections, including methicillin-resistant S
- Business News: Allergan and ZELTIQ Announce Expiration of HSR Waiting Period for Pending Transactionhttps://practicaldermatology.com/news/business-news-allergan-and-zeltiq-announce-expiration-of-hsr-waiting-period-for-pending-transaction/2458225/Allergan is now one step closer to officially acquiring Zeltiq. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") has expired with respect to Allergan's proposed acquisition of ZELTIQ.
- Novan Forms New Advisory Council Focused on Nitric Oxide Technologies in Dermatologyhttps://practicaldermatology.com/news/novan-forms-new-advisory-council-focused-on-nitric-oxide-technologies-in-dermatology/2458228/Novan, Inc. has formed an Advisory Council comprised of key opinion leaders with broad expertise in dermatology. These leading physicians will provide medical advice and drug-development insight to the Company’s senior leadership team and board of directors. The Advisory Council will